

REMARKS

The above amendment re-presents the amendments to the specification and claims made during International Preliminary Examination.

Further, multiple dependency, including improper multiple dependent claims, have been eliminated.

Lastly, non-statutory use claim 8 has been deleted.

Favorable action on the merits is now requested.

Respectfully submitted,

Gordon LOWE

By Matthew Jacob
Matthew Jacob
Registration No. 25,154
Attorney for Applicant

MJ/pjm
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
August 24, 2001


0944264-13001
T00ETT-4924T660

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The paragraph beginning at line 7 and ending at line 19 on page 1 of the specification has be rewritten as follows:

In a first aspect the present invention provides a compound which is a complex formula (I), or an isomer thereof.



wherein

The paragraph beginning at line 22 on page 3 of the specification has been rewritten as follows:

X is preferably hydrogen, halogen such as chlorine, alkoxyl such as methoxyl, ethoxyl, propoxyl, butyloxyl, pentyloxyl, hexyloxyl, heptyloxyl or octyloxyl, preferably ethoxyl, butyloxyl, hexyloxyl or octyloxyl, or aryl such as bromophenyl or tolyl. A substituent may preferably be at the 4' position of the terpyridine system.

The paragraph beginning at line 9 on page 4 of the specification has been rewritten as follows:


X is hydrogen, halogen such as chlorine, alkoxyl such as methoxyl, ethoxyl, propoxyl, butyloxyl, pentyloxyl, hexyloxyl, heptyloxyl or octyloxyl, preferably ethoxyl, butyloxyl,

A

hexyloxyl or octyloxyl, or aryl such as bromophenyl or tolyl; and

The paragraph beginning at line 31 on page 10 and ending at line 12 on page 11 of the specification has been rewritten as follows:

In a further aspect the present invention provides a compound which is a complex of formula (I), or an isomer thereof.




wherein

IN THE CLAIMS:

Claims 1 to 5, 7 and 9 to 10 have been amended as follows:

1. (Amended) A compound which is a complex of formula (I), or an isomer thereof.



wherein

each X, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, aralkyl, alkaryl, acyl, halogen, haloalkyl, haloaryl, hydroxyalkyl, hydroxyaryl, aminoalkyl, aminoaryl, primary, secondary or tertiary amine, hydrazine, alkylhydrazine, alkoxyl, alkylthio, aralkoxyl, nitrile, ester, amide, nitro, azide or aziridino, or is a covalently linked chain which is joined to at least one other complex of formula (I) so as to form a dimeric or oligomeric species, or a covalently linked moiety which provides recognition for a target receptor; and

Y is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aralkyl, heterocyclyl, an inorganic oxyacid or inorganic oxyacid derivative, or a covalently linked chain which is joined to at least one other complex of formula (I) so as to form a dimeric or oligomeric species; or

a pharmaceutically acceptable salt thereof, for use in a method of treatment of the human or animal body by therapy.

2. **(Amended)** A compound as claimed in claim 1 wherein X is hydrogen, halogen or alkoxyl or aryl.

3. **(Amended)** A compound as claimed in claim 1 [or 2] wherein X is hydrogen, chlorine, methoxyl, ethoxyl, propoxyl, butyloxyl, pentyloxyl, hexyloxyl, heptyloxyl, octyloxyl, bromophenyl or tolyl.

4. **(Amended)** A compound as claimed in [any one of claims] claim 1 [to 3] wherein Y is alkyl, [alkaryl] aralkyl, heterocyclyl or an inorganic oxyacid or inorganic oxyacid derivative.

5. **(Amended)** A compound as claimed in [any one of the preceding claims] claim 1 wherein Y is $(CH_2)_nOH$ or $(CH_2)_nNH_3^+$ wherein n is an integer of 1 to 6 or alkyl substituted by one or more amino or carboxy groups; CH_2aryl ; a 5- or 6-membered saturated heterocyclic ring or a 5- or 6-membered unsaturated heterocyclic ring containing at least one N which may

be fused to a 6-membered aryl ring; or SO_3R or PO_3R_2 wherein R is hydrogen or alkyl.

7. (Amended) A compound as claimed in [any one of claims] claim 1 [to 5] which is

2-hydroxyethanethiolate-(2,2':6',2''-terpyridine)platinum (II),

2-hydroxyethanethiolate-(4'-chloro-2,2':6',2''-terpyridine)platinum (II),

2-hydroxyethanethiolate-(4'-ethoxy-2,2':6',2''-terpyridine)platinum (II),

2-hydroxyethanethiolate-(4'-n-butyloxy-2,2':6',2''-terpyridine)platinum (II),

2-hydroxyethanethiolate-(4'-n-hexyloxy-2,2':6',2''-terpyridine)platinum (II),

2-hydroxyethanethiolate-(4'-n-octyloxy-2,2':6',2''-terpyridine)platinum (II),

[2-hydroxyethanthiolate] 2-hydroxyethanethiolate-(4'-p-bromophenyl-2,2':6',2''-terpyridine)platinum (II),

[2-hydroxyethanthiolate] 2-hydroxyethanethiolate-(4'-p-tolyl-2,2':6',2''-terpyridine)platinum (II),

2-aminoethanethiolate-(2,2':6',2''-terpyridine)platinum (II),

pyridine-2-thiolate-(2,2':6',2''-terpyridine)platinum (II),

pyridine-2-thiolate-(4'-chloro-2,2':6',2''-terpyridine)platinum (II),

pyridine-2-thiolate-(4'-ethoxy-2,2':6',2''-terpyridine)platinum (II),

pyridine-2-thiolate-(4'-n-butyloxy-2,2':6',2''-terpyridine)platinum (II),

pyridine-2-thiolate-(4'-n-hexyloxy-2,2':6',2''-terpyridine)platinum (II),

pyridine-2-thiolate-(4'-n-octyloxy-2,2':6',2''-terpyridine)platinum (II),

pyridine-2-thiolate-(4'-p-bromophenyl-2,2':6',2''-terpyridine)platinum (II),

pyridine-2-thiolate-(4'-p-tolyl-2,2':6',2''-terpyridine)platinum (II),

pyridine-4-thiolate-(2,2':6',2''-terpyridine)platinum (II),

pyridine-4-thiolate-(4'-chloro-2,2':6',2''-terpyridine)platinum (II),

pyridine-4-thiolate-(4'-ethoxy-2,2':6',2''-terpyridine)platinum (II),

pyridine-4-thiolate-(4'-n-butyloxy-2,2':6',2''-terpyridine)platinum (II),

pyridine-4-thiolate-(4'-n-hexyloxy-2,2':6',2''-terpyridine)platinum (II),

pyridine-4-thiolate-(4'-n-octyloxy-2,2':6',2''-terpyridine)platinum (II),


pyrimidine-2-thiolate-(2,2':6',2''-terpyridine)platinum (II),

A

pyrimidine-2-thiolate-(4'-chloro-2,2':6',2"-terpyridine)platinum (II),
 pyrimidine-2-thiolate-(4'-ethoxy-2,2':6',2"-terpyridine)platinum (II),
 imidazole-2-thiolate-bis[(2,2':6',2"-terpyridine)platinum (II)],
 imidazole-2-thiolate-bis[(4'-chloro-2,2':6',2"-terpyridine)platinum (II)],
 imidazole-2-thiolate-bis[(4'-ethoxy-2,2':6',2"-terpyridine)platinum (II)],
 imidazole-2-thiolate-bis[(4'-n-butyloxy-2,2':6',2"-terpyridine)platinum (II)],
 imidazole-2-thiolate-bis[(4'-n-hexyloxy-2,2':6',2"-terpyridine)platinum (II)],
 imidazole-2-thiolate-bis[(4'-n-octyloxy-2,2':6',2"-terpyridine)platinum (II)],
 imidazole-2-thiolate-bis[(4'-p-bromophenyl-2,2':6',2"-terpyridine)platinum (II)],
 imidazole-2-thiolate-bis[(4'-p-tolyl-2,2':6',2"-terpyridine)platinum (II)],
 benzimidazole-2-thiolate-bis[(2,2':6',2"-terpyridine)platinum (II)],
 benzimidazole-2-thiolate-bis[(4'-chloro-2,2':6',2"-terpyridine)platinum (II)],
 benzimidazole-2-thiolate-bis[(4'-ethoxy-2,2':6',2"-terpyridine)platinum (II)],
 N,S-bis[(2,2':6',2"-terpyridine)platinum(II)] thioacetimine,
 N,S-bis[(4'-chloro-2,2':6',2"-terpyridine)platinum (II)] thioacetimine,
 [diethylphosphorothioato]
diethylphosphorothiolato (4'-chloro-2,2':6',2"-terpyridine)platinum(II),
 succinylthiolatoplatinum (II) 2,2':6',2"-terpyridine, or
 1-thio-β-D-glucose(2,2':6',2"-terpyridine)platinum (II).

A

9. (Amended) A compound which is a complex of formula (I), or an isomer thereof



wherein

each X, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, aralkyl, alkaryl, acyl, halogen, haloalkyl, haloaryl, hydroxyalkyl, hydroxyaryl, aminoalkyl, aminoaryl, primary, secondary or tertiary amine, hydrazine, alkylhydrazine, alkoxyl, aralkoxyl, nitrile, ester, amide, nitro, azide or aziridino, or is a covalently linked chain which is joined to at least one other complex of formula (I) so as to form a dimeric or oligomeric species, or a covalently linked moiety which provides recognition for a target receptor; and

Y is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aralkyl, heterocyclyl, an inorganic oxyacid or inorganic oxyacid derivative, or a covalently linked chain which is joined to at least one other complex of formula (I) so as to form a dimeric or oligomeric species; or

a pharmaceutically acceptable salt thereof, with the proviso that the complex of formula (I) is not 2-hydroxyethanethiolate(2,2':6',2''-terpyridine)platinum (II) or 2-aminoethanethiolate(2,2':6',2''-terpyridine)platinum (II).

10. (Amended) A pharmaceutical composition comprising a compound as defined in [any one of claims] claim 1 [to 7 or 9] in association with a pharmaceutically acceptable carrier or excipient.